Caleres to Announce First Quarter 2025 Results on May 29
ST. LOUIS--(BUSINESS WIRE)--Caleres (NYSE: CAL), a market-leading portfolio of consumer-driven footwear brands, will release its first quarter 2025 financial results before market open on . Following the announcement, company executives will host a conference call at 10 a.m. Eastern Time to discuss the quarterly results and provide a general business update.
Investors, Caleres associates, media, and the public are invited to join the call. Participants in North America can dial (877) 704-4453, while international callers may use (201) 389-0920; no passcode is required. To participate, please dial in a few minutes before the scheduled start time. The live webcast will also be accessible through Caleres' Investors page.
A replay of the call will be available through Thursday, June 12, 2025, and can be accessed by dialing (844) 512-2921 in North America, or (412) 317-6671 internationally, and using the pin 13753803. A webcast replay will also be archived for a limited period on Caleres' Events & Presentations page.
About Caleres
Caleres is a market-leading portfolio of global footwear brands that includes Famous Footwear, Allen Edmonds, Sam Edelman, Naturalizer, Vionic, and more. Our products are available virtually everywhere - in the 1,000+ retail stores we operate, in hundreds of major department and specialty stores, on our 15 branded e-commerce sites, and on many additional third-party retail platforms. Combined, these brands make Caleres a company with both a legacy and a mission. Our legacy is our nearly 150 years of craftsmanship and our passion for fit, while our mission is to continue to inspire people to feel great… feet first. Visit caleres.com to learn more about us.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
21 minutes ago
- Yahoo
McDonald's Faces Rare Sell Rating as Inflation, Drug Trends Hit Traffic
McDonald's (NYSE:MCD) took a hit Tuesday after Redburn Atlantic downgraded the fast-food giant to Sell its only such rating on the stock. The firm also slashed its price target to $260, about 15% below Monday's close, sending shares briefly below $300 during the session. The call marks a two-notch downgrade from a previous Buy rating, and it reflects deeper concerns about changing customer habits, rising inflation, and the growing impact of weight-loss drugs. Redburn analyst Chris Luyckx said medications like Ozempic could shave $428 million off McDonald's annual system sales roughly 1% and that impact may grow. Meanwhile, the U.S. business is already under pressure: same-store sales dropped 3.6% in Q1, the biggest slide since 2020, and fast-food traffic has declined in 40 of the past 43 months. Even with higher prices and larger average orders, McDonald's may be pricing out its lower-income customer base. Luyckx argued that while the chain typically performs well during downturns, recent price hikes could be damaging its long-held image as an affordable option. Despite the concerns, McDonald's stock is still up 5% this year. But the analyst warned that growth could stall unless the company updates its menu and offers better value. The downgrade extends the stock's losing streak to six days, down from a high above $326 per share in mid-May. This article first appeared on GuruFocus. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Business Wire
27 minutes ago
- Business Wire
Owens & Minor and Rotech Healthcare Mutually Agree to Terminate Previously Announced Acquisition
RICHMOND, Va.--(BUSINESS WIRE)--Owens & Minor, Inc. (NYSE: OMI) today announced it has mutually agreed with Rotech Healthcare Holdings Inc. to terminate the previously announced acquisition. Under the terms of the merger agreement, Owens & Minor has paid $80 million to Rotech Healthcare. Owens & Minor will also redeem the $1 billion of notes issued in April 2025, which include a special mandatory redemption provision in accordance with their terms, and terminate the incremental term loan commitments and senior unsecured bridge loan commitments provided by our lenders which would have been utilized to consummate the acquisition. 'For many months, our teammates, along with the Rotech team, have worked tirelessly in cooperation with the Federal Trade Commission to close this transaction, and while we believe there would have been ample benefits to patients, payors, and providers by adding Rotech to our Patient Direct business, the path to obtain regulatory clearance for this merger proved unviable in terms of time, expense, and opportunity,' said Edward A. Pesicka, President & Chief Executive Officer of Owens & Minor. 'We are confident in our strategy and will continue to focus our efforts on growing our Patient Direct business while remaining committed to strengthening our balance sheet through the use of improved cash flow generation for deleveraging. The home-based care market is a dynamic, growing market, and we are extremely well positioned to help those with chronic conditions get the care and service they need and deserve. Also, we continue to work with a number of interested parties around the potential sale of our Products and Healthcare Services business, and, in the meantime, we will continue to actively work to strengthen that business and tap into its significant upside'. 'I want to thank our teammates, partners and everyone at Rotech for their effort and cooperation over the last several months, and we look forward to a bright future with many years of profitable growth,' Pesicka concluded. About Owens & Minor Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit or follow us on LinkedIn and Instagram. * Registered Trademark or Trademark of O&M Halyard or its affiliates. This press release shall not constitute an offer to buy the notes issued in April 2025, which will be conducted pursuant to a special mandatory redemption in accordance with the terms of the notes.
Yahoo
32 minutes ago
- Yahoo
Brookfield Business Corporation Announces Results of Annual Meeting of Shareholders
BROOKFIELD, NEWS, June 10, 2025 (GLOBE NEWSWIRE) -- Brookfield Business Corporation (the 'Corporation') (NYSE, TSX: BBUC) today announced that all ten nominees proposed for election to the board of directors of the Corporation by holders of class A exchangeable subordinate voting shares ('Exchangeable Shares') and holders of class B multiple voting shares ('Class B Shares') were elected at the Corporation's annual general meeting of shareholders held on June 10, 2025 in a virtual meeting format. Detailed results of the vote for the election of directors are set out below. In accordance with the Corporation's articles, each Exchangeable Share was entitled to one vote per share, representing a 25% voting interest in the Corporation in the aggregate, and the Class B Shares were entitled to a total of 215,082,201 votes in the aggregate, representing a 75% voting interest in the Corporation. The following is a summary of the votes cast by holders of Exchangeable Shares and Class B Shares, voting together as a single class, in regard to the election of the ten directors: Director Nominee Votes For % Votes Withheld % Cyrus Madon 279,593,990 99.90 268,437 0.10 Jeffrey Blidner 277,344,556 99.10 2,517,871 0.90 David Court 279,649,745 99.92 212,682 0.08 Stephen Girsky 279,463,948 99.86 398,479 0.14 David Hamill 279,646,581 99.92 215,846 0.08 Anne Ruth Herkes 279,648,255 99.92 214,172 0.08 John Lacey 272,069,850 97.22 7,792,577 2.78 Don Mackenzie 279,782,671 99.97 79,756 0.03 Michael Warren 279,782,332 99.97 80,095 0.03 Patricia Zuccotti 279,751,664 99.96 110,763 0.04 A summary of all votes cast by holders of the Exchangeable Shares and Class B Shares represented at the Corporation's annual meeting of shareholders is available on SEDAR+ at Brookfield Business Partners is a global business services and industrials company focused on owning and operating high-quality businesses that provide essential products and services and benefit from a strong competitive position. Investors have flexibility to invest in our company either through Brookfield Business Partners L.P. (NYSE: BBU; TSX: a limited partnership, or Brookfield Business Corporation (NYSE, TSX: BBUC). For more information, please visit Brookfield Business Partners is the flagship listed vehicle of Brookfield Asset Management's Private Equity Group. Brookfield Asset Management is a leading global alternative asset manager with over $1 trillion of assets under management. For more information, please contact: Media: Investors: Marie Fuller Alan Fleming Tel: +44 207 408 8375 Tel: +1 (416) 645-2736 Email: Email: in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
